Murae Organisor Ltd
₹ 1.40
-2.78%
08 Nov
- close price
About
Incorporated in 2012, Earum Pharmaceuticals Ltd manufactures and trades in pharma products[1]
Key Points
- Market Cap ₹ 97.6 Cr.
- Current Price ₹ 1.40
- High / Low ₹ 3.10 / 0.98
- Stock P/E
- Book Value ₹ 2.26
- Dividend Yield 0.00 %
- ROCE 0.79 %
- ROE 0.13 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.62 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -45.0% over past five years.
- Company has a low return on equity of 6.02% over last 3 years.
- Company has high debtors of 1,543 days.
- Working capital days have increased from 2,477 days to 6,342 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00 | 8.83 | 18.57 | 23.34 | 35.42 | 50.70 | 55.11 | 41.08 | 21.04 | 14.95 | 2.54 | 1.46 | |
0.00 | 0.00 | 8.62 | 18.06 | 22.91 | 33.85 | 47.40 | 53.87 | 48.84 | 25.46 | 13.17 | 3.67 | 2.53 | |
Operating Profit | 0.00 | 0.00 | 0.21 | 0.51 | 0.43 | 1.57 | 3.30 | 1.24 | -7.76 | -4.42 | 1.78 | -1.13 | -1.07 |
OPM % | 2.38% | 2.75% | 1.84% | 4.43% | 6.51% | 2.25% | -18.89% | -21.01% | 11.91% | -44.49% | -73.29% | ||
0.00 | 0.00 | 0.01 | 0.06 | 0.35 | 0.41 | 0.05 | 2.27 | 8.93 | 7.70 | 1.41 | 1.52 | 0.00 | |
Interest | 0.00 | 0.00 | 0.06 | 0.39 | 0.52 | 0.72 | 1.04 | 0.97 | 0.93 | 0.08 | 0.29 | 0.26 | 0.01 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 | 0.04 | 0.10 | 0.12 | 0.12 | 0.10 | 0.06 | 0.06 |
Profit before tax | 0.00 | 0.00 | 0.16 | 0.16 | 0.24 | 1.24 | 2.27 | 2.44 | 0.12 | 3.08 | 2.80 | 0.07 | -1.14 |
Tax % | 31.25% | 43.75% | 33.33% | 26.61% | 27.31% | 25.82% | 25.00% | 27.92% | 28.93% | 28.57% | |||
0.00 | 0.00 | 0.11 | 0.10 | 0.16 | 0.91 | 1.66 | 1.82 | 0.09 | 2.22 | 1.98 | 0.05 | -1.03 | |
EPS in Rs | 0.00 | 0.00 | 1.10 | 0.20 | 0.32 | 0.61 | 1.11 | 0.06 | 0.00 | 0.07 | 0.06 | 0.00 | -0.05 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -45% |
3 Years: | -60% |
TTM: | -87% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | -50% |
3 Years: | -18% |
TTM: | -174% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | -25% |
3 Years: | -51% |
1 Year: | 31% |
Return on Equity | |
---|---|
10 Years: | 9% |
5 Years: | 6% |
3 Years: | 6% |
Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.01 | 0.01 | 0.01 | 0.11 | 0.11 | 0.31 | 0.31 | 6.17 | 6.17 | 12.34 | 12.34 | 49.42 |
Reserves | 0.00 | 0.00 | 0.86 | 1.26 | 1.42 | 4.61 | 5.64 | 8.25 | 8.33 | 4.39 | 6.37 | 6.42 |
0.00 | 0.00 | 1.14 | 1.90 | 2.06 | 7.21 | 9.58 | 9.28 | 11.33 | 8.74 | 8.74 | 0.00 | |
0.00 | 0.00 | 2.54 | 5.51 | 7.49 | 7.38 | 7.73 | 12.45 | 2.04 | 3.33 | 1.14 | 64.03 | |
Total Liabilities | 0.01 | 0.01 | 4.55 | 8.78 | 11.08 | 19.51 | 23.26 | 36.15 | 27.87 | 28.80 | 28.59 | 119.87 |
0.00 | 0.00 | 0.04 | 0.17 | 0.16 | 0.20 | 0.48 | 0.80 | 0.76 | 0.58 | 0.48 | 0.00 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.03 | 0.00 | 0.00 | 0.00 | 0.00 |
0.01 | 0.01 | 4.51 | 8.61 | 10.92 | 19.31 | 22.78 | 32.32 | 27.11 | 28.22 | 28.11 | 119.87 | |
Total Assets | 0.01 | 0.01 | 4.55 | 8.78 | 11.08 | 19.51 | 23.26 | 36.15 | 27.87 | 28.80 | 28.59 | 119.87 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00 | -1.80 | -0.26 | 0.09 | -7.09 | -0.48 | -3.45 | -7.10 | 2.61 | 0.26 | -15.92 | |
0.00 | 0.00 | -0.04 | -0.15 | -0.02 | -0.05 | -0.32 | -3.45 | 2.94 | 0.06 | 0.00 | -0.48 | |
0.00 | 0.00 | 1.84 | 0.77 | -0.25 | 6.98 | 0.94 | 6.76 | 2.90 | -2.67 | -0.29 | 28.08 | |
Net Cash Flow | 0.00 | 0.00 | 0.00 | 0.35 | -0.18 | -0.16 | 0.14 | -0.14 | -1.26 | -0.01 | -0.03 | 11.69 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 124.84 | 87.47 | 55.99 | 111.19 | 78.11 | 112.26 | 94.80 | 260.91 | 204.84 | 1,543.35 | ||
Inventory Days | 70.52 | 77.88 | 108.46 | 91.19 | 86.30 | 97.05 | 121.96 | 178.56 | 391.86 | 1,438.74 | ||
Days Payable | 112.93 | 107.21 | 82.75 | 77.11 | 53.85 | 83.42 | 10.18 | 17.64 | -27.76 | 7.09 | ||
Cash Conversion Cycle | 82.43 | 58.13 | 81.69 | 125.27 | 110.56 | 125.89 | 206.58 | 421.84 | 624.46 | 2,975.00 | ||
Working Capital Days | 81.43 | 54.05 | 57.71 | 115.72 | 98.27 | 125.91 | 222.31 | 430.92 | 657.98 | 6,341.52 | ||
ROCE % | 0.00% | 21.78% | 20.83% | 22.16% | 24.94% | 23.93% | 17.38% | 4.24% | 12.32% | 11.68% | 0.79% |
Documents
Announcements
-
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Thursday, 14Th November, 2024
17h - Board meeting to approve financial results on 14th November.
-
Board Meeting Outcome for Outcome And Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
20h - Appointment of new Managing Director and resignation of current MD.
-
Board Meeting Outcome for Revised Outcome
28 Oct - Revised outcome of Board meeting for Rights Issue.
-
Intimation Of Trading Approval Received For Preferential Issue Of Fully Paid-Up Equity Shares Pursuant To Conversion Of Warrants By Murae Organisor Limited (Formerly Known As Earum Pharmaceuticals Limited) ('The Company') Under Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements)
22 Oct - Trading approval received for preferential issue of equity shares.
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E., 15Th October, 2024
15 Oct - Increase in authorized share capital and rights issue.
Business Overview:[1]
Company is in the pharmaceutical business handling marketing, trading and distribution of a wide range of pharmaceutical formulation products, of which 120 products are marketed by company under its own brand, and their manufacturing is outsourced to third parties. Apart from this, company also trades in active pharmaceutical ingredients